OncoTargets and therapy最新文献

筛选
英文 中文
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France 奥希替尼耐药突变 L718Q 或 G724S 出现后表皮生长因子受体突变阳性 NSCLC 患者的特征:法国一项多中心回顾性观察研究
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-29 DOI: 10.2147/ott.s448909
Mateo Sanchis-Borja, Florian Guisier, Aurélie Swalduz, Hubert Curcio, Victor Basse, Christophe Maritaz, Christos Chouaid, Jean-Bernard Auliac
{"title":"Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France","authors":"Mateo Sanchis-Borja, Florian Guisier, Aurélie Swalduz, Hubert Curcio, Victor Basse, Christophe Maritaz, Christos Chouaid, Jean-Bernard Auliac","doi":"10.2147/ott.s448909","DOIUrl":"https://doi.org/10.2147/ott.s448909","url":null,"abstract":"<strong>Purpose:</strong> The third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimertinib, is an effective first-line therapy for patients with common <em>EGFR</em> mutation-positive non-small cell lung cancer (NSCLC). However, almost all patients become resistant to treatment. In some patients, emergence of tertiary <em>EGFR</em> mutations is implicated as a resistance mechanism. This study describes patients with NSCLC who acquired the rare <em>EGFR</em> mutations, L718Q or G724S, following EGFR TKI treatment.<br/><strong>Patients and Methods:</strong> This was a retrospective, observational study undertaken in France from Feb–Nov 2021, in patients with <em>EGFR</em> mutation-positive NSCLC with an acquired L718Q or G724S mutation. Primary objectives were description of tumor characteristics, progression, and progression under treatment.<br/><strong>Results:</strong> Nine eligible patients were identified. Acquired resistance to initial EGFR TKI treatment was associated with T790M emergence in six patients, who then received osimertinib monotherapy. Overall, eight patients received osimertinib monotherapy treatment at some point (average treatment duration: 18.3 months). Following the emergence of L718Q or G724S, patients received chemotherapy (n = 4; two of whom subsequently received afatinib), nivolumab (n = 2), afatinib (n = 2), or immunochemotherapy (n = 1). In the four patients who received afatinib after identification of L718Q or G724S, 2 achieved a partial response, one had stable disease and one had progressive disease. Treatment duration was 1.6– 31.7 months. In patients with controlled disease (n = 3), progression-free survival was 6.1– 31.7 months. Two of these patients had previously received osimertinib.<br/><strong>Conclusion:</strong> Currently, there is no consensus regarding the treatment of <em>EGFR</em> mutation-positive NSCLC following emergence of the osimertinib resistance mutations, L718Q or G724S. Afatinib appears to be a promising treatment option in this setting.<br/><br/><strong>Keywords:</strong> osimertinib, afatinib, real-world evidence, tertiary <em>EGFR</em> mutations<br/>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141165649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification and Validation of Nicotinamide Metabolism-Related Gene Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma 烟酰胺代谢相关基因特征的鉴定和验证作为肝细胞癌的新型预后模型
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-28 DOI: 10.2147/ott.s464709
Sijia Yang, Ang Li, Lihong Lv, Jinxin Duan, Zhihua Zheng, Wenfeng Zhuo, Jun Min, Jinxing Wei
{"title":"Identification and Validation of Nicotinamide Metabolism-Related Gene Signatures as a Novel Prognostic Model for Hepatocellular Carcinoma","authors":"Sijia Yang, Ang Li, Lihong Lv, Jinxin Duan, Zhihua Zheng, Wenfeng Zhuo, Jun Min, Jinxing Wei","doi":"10.2147/ott.s464709","DOIUrl":"https://doi.org/10.2147/ott.s464709","url":null,"abstract":"<strong>Background:</strong> Nicotinamide (NAM+) regulates redox and metabolic activities in the mitochondria. The intention of the research was to identify key genes that relate to nicotinamide in hepatocellular carcinoma (HCC).<br/><strong>Methods:</strong> Relevant clinical information were collected as well as RNA-seq data using the Cancer Genome Atlas (TCGA) database. Differential analysis was used to discover the genes that were differently expressed. On the key genes associated with NAM, functional enrichment analysis was carried out. Next, receiver operating characteristic (ROC) and prognosis Kaplan-Meier (K-M) curve analyses were used to evaluate the importance of important gene expression, respectively. The immune cell signatures were estimated using the CIBERSORT algorithm. Finally, the anticancer impact of NAM on HCC was experimentally confirmed, and important genes NADSYN1 and NT5C were validated at the protein level in clinical specimens.<br/><strong>Results:</strong> Six prognostic key genes (NAXE, NADSYN1, NT5C, NT5C3A, PNP and NT5E) were identified. There is an association between the level of key gene expression and the clinical prognosis. Four key genes (NAXE, NADSYN1, NT5C and NT5C3A) have statistical significance of survival prognosis. Finally, the expression of NAM-related genes and the inhibitory effect of NAM on HCC were verified by experiments.<br/><strong>Conclusion:</strong> The study first found some Nicotinamide metabolism-related differentially expressed genes (NMRDEGs) that are related to HCC can contribute to predicting survival and monitoring the treatment.<br/><br/>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141165644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MCM5 is a Novel Therapeutic Target for Glioblastoma MCM5 是胶质母细胞瘤的新型治疗靶点
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-13 DOI: 10.2147/ott.s457600
Jian Zhou, Housheng Zheng, Huiru Zhang, Wenqiang Yu, Baoer Li, Liang Ye, Lu Wang
{"title":"MCM5 is a Novel Therapeutic Target for Glioblastoma","authors":"Jian Zhou, Housheng Zheng, Huiru Zhang, Wenqiang Yu, Baoer Li, Liang Ye, Lu Wang","doi":"10.2147/ott.s457600","DOIUrl":"https://doi.org/10.2147/ott.s457600","url":null,"abstract":"<strong>Objective:</strong> MCM5 is a DNA licensing factor involved in cell proliferation and has been previously established as an excellent biomarker in a number of malignancies. Nevertheless, the role of MCM5 in GBM has not been fully clarified. The present study aimed to investigate the potential roles of MCM5 in the treatment of GBM and to elucidate its underlying mechanism, which is beneficial for developing new therapeutic strategies and predicting prognosis.<br/><strong>Methods:</strong> Firstly, we obtained transcriptomic and proteomic data from the TCGA and CPTAC databases on glioma patients. Employing the DeSeq2 R package, we then identified genes with joint differential expression in GBM tissues subjected to chemotherapy. To develop a prognostic risk score model, we performed univariate and multivariate Cox regression analyses. In vitro knockdown and overexpression of MCM5 were used to further investigate the biological functions of GBM cells. Additionally, we also delved into the upstream regulation of MCM5, revealing associations with several transcription factors. Finally, we investigated differences in immune cell infiltration and drug sensitivity across diverse risk groups identified in the prognostic risk model.<br/><strong>Results:</strong> In this study, the chemotherapy-treated GBM samples exhibited consistent alterations in 46 upregulated and 94 downregulated genes at both the mRNA and protein levels. Notably, MCM5 emerged as a gene with prognostic significance as well as potential therapeutic relevance. In vitro experiments subsequently validated the role of increased MCM5 expression in promoting GBM cell proliferation and resistance to TMZ. Correlations with transcription factors such as CREB1, CTCF, NFYB, NRF1, PBX1, TEAD1, and USF1 were discovered during upstream regulatory analysis, enriching our understanding of MCM5 regulatory mechanisms. The study additionally delves into immune cell infiltration and drug sensitivity, providing valuable insights for personalized treatment approaches.<br/><strong>Conclusion:</strong> This study identifies MCM5 as a key player in GBM, demonstrating its prognostic significance and potential therapeutic relevance by elucidating its role in promoting cell proliferation and resistance to chemotherapy.<br/><br/><strong>Keywords:</strong> glioblastoma, minichromosome maintenance protein 5, chemotherapeutic drug resistance<br/>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140927974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Noncoding RNA NEAT1 Promotes Cell Proliferation and Invasion and Suppresses Apoptosis in Hepatocellular Carcinoma by Regulating miRNA-22-3p/akt2 in vitro and in vivo [Retraction] 长非编码 RNA NEAT1 在体内外通过调控 miRNA-22-3p/akt2 促进肝细胞癌细胞增殖和侵袭并抑制其凋亡 [Retraction] (撤回)
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-07 DOI: 10.2147/ott.s476432
Xichang Zhou, Xiang Wang, Yizhou Zhou, Long Cheng, Youwei Zhang, Yangmei Zhang
{"title":"Long Noncoding RNA NEAT1 Promotes Cell Proliferation and Invasion and Suppresses Apoptosis in Hepatocellular Carcinoma by Regulating miRNA-22-3p/akt2 in vitro and in vivo [Retraction]","authors":"Xichang Zhou, Xiang Wang, Yizhou Zhou, Long Cheng, Youwei Zhang, Yangmei Zhang","doi":"10.2147/ott.s476432","DOIUrl":"https://doi.org/10.2147/ott.s476432","url":null,"abstract":"Retraction for the article Long Noncoding RNA NEAT1 Promotes Cell Proliferation And Invasion And Suppresses Apoptosis In Hepatocellular Carcinoma By Regulating miRNA-22-3p/akt2 In Vitro And In Vivo","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140887807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synchronous Multiple Primary Malignant Adenocarcinoma of the Descending Colon and Fungating Bleeding Adenocarcinoma of the Terminal Ileum Presenting Massive Rectal Bleeding: A Trap for the Unwary 降结肠同步多发性原发性恶性腺癌和末端回肠出血性腺癌并发大量直肠出血:不明真相者的陷阱
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-02 DOI: 10.2147/ott.s453682
Baicheng Li, Zhao Chen, Guangzhi Wang, Yaqing Liu, Shili Ning
{"title":"Synchronous Multiple Primary Malignant Adenocarcinoma of the Descending Colon and Fungating Bleeding Adenocarcinoma of the Terminal Ileum Presenting Massive Rectal Bleeding: A Trap for the Unwary","authors":"Baicheng Li, Zhao Chen, Guangzhi Wang, Yaqing Liu, Shili Ning","doi":"10.2147/ott.s453682","DOIUrl":"https://doi.org/10.2147/ott.s453682","url":null,"abstract":"<strong>Abstract:</strong> Primary cancer of the ileum is rare, and when it occurs in conjunction with primary colon cancer, it becomes even more infrequent and challenging to diagnose prior to surgical intervention. Primary small bowel cancers can be overlooked and may be misidentified as small bowel mesenchymal tumours or advanced metastases from colon cancer. We present an exceedingly uncommon case of ruptured primary ileal cancer combined with primary descending colon cancer presenting with gastrointestinal bleeding. Based on our understanding, instances of dual tumours concurrently occurring are exceedingly infrequent. In this patient, there was a preoperative suspicion of bleeding from colon cancer in the descending region. However, intraoperative exploration revealed that the location of the bleeding was a terminal ileal mass. Following the surgical intervention, the patient recovered satisfactorily. Intraoperative exploration of the entire gastrointestinal tract is therefore necessary in patients with gastrointestinal haemorrhage, especially in those who require urgent surgery without adequate preoperative investigations. If a mass is detected at the end of the ileum, intraoperative pathology should be performed if feasible. Subsequently, if the diagnosis reveals an adenocarcinoma, terminal ileocolic resection and right hemicolectomy are necessary for appropriate resection.<br/><br/><strong>Keywords:</strong> multiple primary malignant neoplasms, gut bleeding, adenocarcinoma of the small bowel, descending colon cancer, gastrointestinal tumours, case report<br/>","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140835843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miRNA-99b-5p Targets FZD8 to Inhibit Non-Small Cell Lung Cancer Proliferation, Migration and Invasion [Retraction] miRNA-99b-5p靶向FZD8抑制非小细胞肺癌的增殖、迁移和侵袭 [撤稿]
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-01 DOI: 10.2147/ott.s479422
Rui Liu, Yajuan Chen, Tao Shou, Jing Hu, Chen Qing
{"title":"miRNA-99b-5p Targets FZD8 to Inhibit Non-Small Cell Lung Cancer Proliferation, Migration and Invasion [Retraction]","authors":"Rui Liu, Yajuan Chen, Tao Shou, Jing Hu, Chen Qing","doi":"10.2147/ott.s479422","DOIUrl":"https://doi.org/10.2147/ott.s479422","url":null,"abstract":"","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141133354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date 评估Durvalumab对局部晚期或转移性胆管癌成人患者的治疗潜力:迄今为止的证据
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-01 DOI: 10.2147/ott.s391707
Michael Storandt, Zhaohui Jin, Amit Mahipal
{"title":"Evaluating the Therapeutic Potential of Durvalumab in Adults with Locally Advanced or Metastatic Biliary Tract Cancer: Evidence to Date","authors":"Michael Storandt, Zhaohui Jin, Amit Mahipal","doi":"10.2147/ott.s391707","DOIUrl":"https://doi.org/10.2147/ott.s391707","url":null,"abstract":"","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141033755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Testosterone Exacerbates the Formation of Liver Cancer Induced by Environmental N-Nitrosamines Exposure: Potential Mechanisms and Implications for Human Health 睾酮会加剧因暴露于环境中的 N-亚硝胺而诱发的肝癌的形成:潜在机制及其对人类健康的影响
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-01 DOI: 10.2147/ott.s456746
Xin Yin, Hong-Wei Gu, Dan Ning, Yu-Sang Li, He-Bin Tang
{"title":"Testosterone Exacerbates the Formation of Liver Cancer Induced by Environmental N-Nitrosamines Exposure: Potential Mechanisms and Implications for Human Health","authors":"Xin Yin, Hong-Wei Gu, Dan Ning, Yu-Sang Li, He-Bin Tang","doi":"10.2147/ott.s456746","DOIUrl":"https://doi.org/10.2147/ott.s456746","url":null,"abstract":"","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141028584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scalp Metastasis After Breast Cancer Surgery: A Case Report 乳腺癌手术后的头皮转移:病例报告
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-05-01 DOI: 10.2147/ott.s456532
Jingxuan Wu, Wenzhu Zhang, Hong Zhang, Xingjia Lu, Biqing Luan, Qizhi Yang, Liang Chen, Wenlin Chen, Fei Ge
{"title":"Scalp Metastasis After Breast Cancer Surgery: A Case Report","authors":"Jingxuan Wu, Wenzhu Zhang, Hong Zhang, Xingjia Lu, Biqing Luan, Qizhi Yang, Liang Chen, Wenlin Chen, Fei Ge","doi":"10.2147/ott.s456532","DOIUrl":"https://doi.org/10.2147/ott.s456532","url":null,"abstract":"","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141134837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long Non-Coding RNA TRG-AS1 Promoted Proliferation and Invasion of Lung Cancer Cells Through the miR-224-5p/SMAD4 Axis [Retraction] 长非编码 RNA TRG-AS1 通过 miR-224-5p/SMAD4 轴促进肺癌细胞的增殖和侵袭 [撤稿]
IF 4 4区 医学
OncoTargets and therapy Pub Date : 2024-04-18 DOI: 10.2147/ott.s474055
Mengyan Zhang, Weiguo Zhu, Mansour Haeryfar, Sumei Jiang, Xiang Jiang, Wei Chen, Jiancheng Li
{"title":"Long Non-Coding RNA TRG-AS1 Promoted Proliferation and Invasion of Lung Cancer Cells Through the miR-224-5p/SMAD4 Axis [Retraction]","authors":"Mengyan Zhang, Weiguo Zhu, Mansour Haeryfar, Sumei Jiang, Xiang Jiang, Wei Chen, Jiancheng Li","doi":"10.2147/ott.s474055","DOIUrl":"https://doi.org/10.2147/ott.s474055","url":null,"abstract":"Retraction for the article Long Non-Coding RNA TRG-AS1 Promoted Proliferation and Invasion of Lung Cancer Cells Through the miR-224-5p/SMAD4 Axis","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140617206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信